EULAR 2018 Review

More documents

Recommendations

Info

EULAR 2018 Conference Highlights Chairman’s Welcome Dear CSF Member, It is my pleasure to bring to you our review of the EULAR 2018 highlights, including a review of my ‘Chairman’s picks’. This year, there continues to be considerable data published on JAK inhibition, with differences in the JAK-STAT signalling pathway in synovial fibroblasts analysed in different joints [#OP0165], and the results of a systematic review and meta-analysis of Phase 2 and 3 JAK inhibitor studies presented for the risk of patients developing malignancies or serious infections [#OP0032]. It was exciting to see the Phase 3 data for upadacitinib: Burmester et al shared the results from patients with an inadequate response to csDMARDs [#OP0036]; Genovese et al, presented the safety and efficacy of upadacitinib in bDMARD inadequate responders [#SAT0219]; and Smolen et al evaluated updacitinib as monotherapy [#OP0035]. We also saw the results of a Phase 2b/3 study of upadactinib in Japanese patients [#SAT0257]. Tofacitinib continues to be prominent this year: data from the ORAL Strategy trial were presented, including the impact of glucocorticoids on tofacitinib efficacy and safety [#SAT0247], and the effect of live zoster vaccination [#SAT0220]; while Kaine et al presented data on tofacitinib discontinuation and re-initiation in long-term extension studies [#OP0037]. Specific considerations included a comparison of the effectiveness of tofacitinib and bDMARDs in clinical practice [#AB0485], improvements in left ventricular mass and cardiac output [#AB0489]; and identification of subgroups, which could be used to develop personalised treatment algorithms [SAT0217]. Baricitinib showed interesting and varied data, with post hoc analyses from Phase 3 trials examining the impact of controlling disease activity on physical function, and pain [#AB0258]. The effects of dose reduction were investigated [#SAT0253] and hepatitis B reactivation was examined [#FRI0077]; efficacy and safety of baricitinib were reported from the Phase 3 study RA-BALANCE, which enrolled patients in China, Argentina and Brazil [#SAT0218]. Beyond RA, there were data in psoriatic arthritis (PsA); the effects of tofacitinib on several composite endpoint measures were presented from OPAL Broaden and Beyond [#THU0323]; and efficacy analysed by background methotrexate dose [#AB0902], and by baseline demographics, disease activity and concomitant medications [#AB0921]. The efficacy and safety of tofacitinib in patients with or without metabolic syndrome were also compared [SAT0317]. The safety, tolerability and efficacy of tofacitinib over 36 months were presented from the ongoing OPAL Balance study [SAT0293]. Also of interest was an evaluation of the effect of tofacitinib on the ability of monocytes to differentiate into dendritic cells, an important step in innate immunity [#AB0046]. The following pages provide a review of the highlights from EULAR 2018. Once again, thank you for your support, and we hope you enjoyed your time at EULAR. Yours, Prof. Iain McInnes
Highlights from EULAR 2018 During the EULAR 2018 annual meeting, many presentations and posters reported on cytokine signalling and related drugs. This document reviews the highlights. Oral presentations Abstract Session: RA therapy - new molecules and new strategies Upadacitinib Phase 3 results Phase 3 results for upadacitinib in 661 patients with RA and inadequate response (IR) to csDMARDs were reported in an oral presentation by Burmester, et al. At Week 12, significantly more patients receiving upadacitinib 15 mg and 30 mg QD versus placebo achieved an ACR20 response (63.8% and 66.2% vs 35.7%, P
Page 1: Enhancing knowledge of the clinical
Page 5 and 6: Poster Sessions Poster Tour: Novel
Page 7 and 8: Poster sessions I, II and III Upada
Page 9 and 10: treatment with tofacitinib lead to
Page 11 and 12: Baricitinib dose step-down followin
Page 13 and 14: Publication only Efficacy and safet
Page 15 and 16: A case study of vasculitis in a pat
Page 17 and 18: In a separate dedicated Phase 1 stu
Page 19 and 20: • Helliwell P, Coates LC, FitzGer
Page 21: Enhancing knowledge of the clinical

EULAR 2018 Review

Create successful ePaper yourself

Delete template?

Save as template?